A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy

J Hematol Oncol. 2024 Nov 28;17(1):116. doi: 10.1186/s13045-024-01635-5.

Abstract

CAR-macrophage has promising prospect in treating solid tumors, due to its high infiltration into tumors, and its dual roles in phagocytosis and immune modulation. Here we show the clinical results of CAR-macrophage treatment of two ovarian cancer patients. The CAR-macrophages were produced by introducing a mesothelin targeting CAR to patients' primary peripheral blood mononuclear cell-derived macrophages, and the products were infused to patients intravenously. Our data show good safety of the infusion product, and the efficacy can be further improved. Intraperitoneal infusion of CAR-macrophages has proven effective in treating intraperitoneal tumors in a preclinical model, paving the way for demonstrating proof-of-concept clinical efficacy of CAR-macrophages in the treatment of intraperitoneal tumors.

Keywords: Autologous macrophage; Chimera antigen receptor (CAR); Mesothelin; Ovarian cancer.

Publication types

  • Letter

MeSH terms

  • Animals
  • Female
  • GPI-Linked Proteins* / immunology
  • Humans
  • Immunotherapy, Adoptive / adverse effects
  • Immunotherapy, Adoptive / methods
  • Macrophages* / immunology
  • Mesothelin*
  • Ovarian Neoplasms* / immunology
  • Ovarian Neoplasms* / therapy
  • Receptors, Chimeric Antigen* / immunology
  • Receptors, Chimeric Antigen* / therapeutic use

Substances

  • Mesothelin
  • GPI-Linked Proteins
  • Receptors, Chimeric Antigen